In addition, the GO-203/decitabine combination was found to confer synergistic killing of AML cell lines and primary AML blasts, indicating that targeting DNMT1 with GO-203 and decitabine is potentially a highly effective approach for the treatment of AML. The gene discussed is DNMT1; the disease is acute myeloid leukemia.